ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Hyperglycolysis in endothelial cells drives endothelial injury and microvascular alterations in peritoneal dialysis

Si, Zekun; Su, Wenyan; Zhou, Zhuoyu; Li, Jinjin; Su, Cailing; Zhang, Ying; Hu, Zuoyu; Huang, Zhijie; Zhou, Hong; Cong, Ansheng; Zhou, Zhanmei; Cao, Wei*广州医学院; 南方医科大学
Clinical and Translational Medicine2023-12DOI: 10.1002/ctm2.1498
13阅读
引用收藏
分享

摘要

BackgroundEndothelial cell (EC) dysfunction leading to microvascular alterations is a hallmark of technique failure in peritoneal dialysis (PD). However, the mechanisms underlying EC dysfunction in PD are poorly defined.MethodsWe combined RNA sequencing with metabolite set analysis to characterize the metabolic profile of peritoneal ECs from a mouse model of PD. This was combined with EC-selective blockade of glycolysis by genetic or pharmacological inhibition of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) in vivo and in vitro. We also investigated the association between peritoneal EC glycolysis and microvascular alterations in human peritoneal samples from patients with end-stage kidney disease (ESKD).ResultsIn a mouse model of PD, peritoneal ECs had a hyperglycolytic metabolism that shunts intermediates into nucleotide synthesis. Hyperglycolytic mouse peritoneal ECs displayed a unique active phenotype with increased proliferation, permeability and inflammation. The active phenotype of mouse peritoneal ECs can be recapitulated in human umbilical venous ECs and primary human peritoneal ECs by vascular endothelial growth factor that was released from high glucose-treated mesothelial cells. Importantly, reduction of peritoneal EC glycolysis, via endothelial deficiency of the glycolytic activator PFKFB3, inhibited PD fluid-induced increases in peritoneal capillary density, vascular permeability and monocyte extravasation, thereby protecting the peritoneum from the development of structural and functional damages. Mechanistically, endothelial PFKFB3 deficiency induced the protective effects in part by inhibiting cell proliferation, VE-cadherin endocytosis and monocyte-adhesion molecule expression. Pharmacological PFKFB3 blockade induced a similar therapeutic benefit in this PD model. Human peritoneal tissue from patients with ESKD also demonstrated evidence of increased EC PFKFB3 expression associated with microvascular alterations and peritoneal dysfunction.ConclusionsThese findings reveal a critical role of glycolysis in ECs in mediating the deterioration of peritoneal function and suggest that strategies targeting glycolysis in peritoneal ECs may be of therapeutic benefit for patients undergoing PD. @@@ Peritoneal endothelial cells have a hyperglycolytic metabolism during peritoneal dialysis (PD).Endothelial PFKFB3 deficiency/blockade inhibits PD fluid-induced peritoneal microvascular alterations, thereby protecting the peritoneum from the development of structural and functional damages.Mechanistically, endothelial PFKFB3 deficiency induces the protective effects in part by inhibiting cell proliferation, VE-cadherin endocytosis and monocyte-adhesion molecule expression.image

学科与关键词

关键词
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3glycolysismicrovascular alterationsperitoneal dialysisperitoneal endothelial cells
相关
加载中…
  • PFKP Activation Ameliorates Foot Process Fusion in Podocytes in Diabetic Kidney Disease
    Zhang, Zongwei; Liang, Wei*; Luo, Qiang; Hu, Hongtu; Yang, Keju; Hu, Jijia; Chen, Zhaowei; Zhu, Jili; Feng, Jun; Zhu, Zijing; Chi, Qingjia; Ding, Guohua*Frontiers in Endocrinology, 2022, 12: 797025.被引 8
  • Blockade of prostaglandin E2 receptor 4 ameliorates peritoneal dialysis-associated peritoneal fibrosis
    Luo, Qimei; Liu, Mi; Tan, Yanhong; Chen, Jinzhong; Zhang, Wei; Zhong, Shaoxin; Pan, Jianyi; Zheng, Qingkun; Gong, Lewei; Su, Lijuan; Jia, Zhanjun*; Dou, Xianrui*Frontiers in Pharmacology, 2022, 13: 1004619.被引 1
  • PPARγ alleviates peritoneal fibrosis progression along with promoting GLUT1 expression and suppressing peritoneal mesothelial cell proliferation
    Feng, Junxia; Lu, Meizhi; Li, Wenhao; Li, Jingchun; Meng, Ping; Li, Zukai; Gao, Xuejuan*; Zhang, Yunfang*Molecular and Cellular Biochemistry, 2022, 477(7): 1959-1971.被引 5
查看全部 →

发表信息

论文状态
公开发表
期刊
Clinical and Translational Medicine
发表日期
2023-12
卷期
第 13 卷, 第 12 期
页码
e1498
DOI
10.1002/ctm2.1498
成果收录
SCIE
资助标注
National Natural Science Foundation of China; National Key Research and Development Program of China [2021YFC2500200]; Key Technologies R&D Program of Guangdong Province [2023B1111030004]; [82270776]; [82330020]

作者

  • S

    Si, Zekun (第一作者)

    southern med univ

  • S

    Su, Wenyan

    southern med univ

查看全部 12 位作者收起作者
  • Z

    Zhou, Zhuoyu

    southern med univ

  • L

    Li, Jinjin

    southern med univ

  • S

    Su, Cailing

    southern med univ

  • Z

    Zhang, Ying

    2 · guangzhou med univ

  • H

    Hu, Zuoyu

    southern med univ

  • H

    Huang, Zhijie

    southern med univ

  • Z

    Zhou, Hong

    southern med univ

  • C

    Cong, Ansheng

    southern med univ

  • Z

    Zhou, Zhanmei

    southern med univ

  • C

    Cao, Wei (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417